Rainbow BioSciences, the biotech division of Rainbow Coral, this morning told investors that it is nearing a definitive agreement with a leading, Texas-based genetic testing laboratory.
One of the fastest-growing segments of the global biotech industry, the genetic testing sector is projected to reach $2.2 billion by 2017. The laboratory in negotiations with RBCC specializes in the cutting-edge science of pharmacogenomics, a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans.
Pharmacogenomics could be the key to truly personalized medicine, which RBCC views as the future of healthcare. For more information on Rainbow BioSciences’ personalized medicine initiatives, visit www.rainbowbiosciences.com.
While continually seeking out new partnerships with biotechnology developers, Rainbow BioSciences is focused on developing new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT), and Amgen Inc. (NASDAQ: AMGN).
Let us hear your thoughts: Rainbow Coral Corp. Message Board